Impact of gender on response to immune checkpoint inhibitors in patients with non-small cell lung cancer undergoing second- or later-line treatment

BACKGROUND: Several previous clinical trials have reported that male patients with non-small cell lung cancer (NSCLC) respond better to immunotherapy than females. However, the impact of gender on prognosis remains uncertain because no real-world study considering various factors that affect patient...

Descripción completa

Detalles Bibliográficos
Autores principales: Choi, Myeong Geun, Choi, Chang-Min, Lee, Dae Ho, Kim, Sang-We, Yoon, Shinkyo, Ji, Wonjun, Lee, Jae Cheol
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9554675/
https://www.ncbi.nlm.nih.gov/pubmed/36248340
http://dx.doi.org/10.21037/tlcr-22-146

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9554675/
https://www.ncbi.nlm.nih.gov/pubmed/36248340
http://dx.doi.org/10.21037/tlcr-22-146

Ejemplares similares